Body Mass Index Impacts In Vitro Fertilization Stimulation (original) (raw)
Related papers
The influence of body mass index on in vitro fertilization outcome
International Journal of Gynecology & Obstetrics, 2009
Objective: To examine whether body mass index (BMI) influences the outcome of in vitro fertilization (IVF). Methods: We studied 516 IVF cycles, 438 undergone by nonobese (BMI ≤ 30) and 78 by obese (BMI N 30) women who all had an a priori favorable prognosis (age b 40 years and first, second, or third IVF cycle). Results: Pregnancy was achieved in 122 (27.9%) nonobese and 12 (15.4%) obese women. The obese women required significantly longer stimulation and more gonadotropin ampoules, and had lower peak estradiol levels and a significantly lower fertilization rate; obese poor responders had a significantly lower pregnancy rate than nonobese poor responders; and the prevalence of poor responders was significantly higher among obese than nonobese women (28.2% vs 16.9%, P b 0.04). Conclusion: While the likelihood of poor responders was increased among obese women, reasonable conception rates were achieved in nonobese poor responders, and were comparable to the rates in nonobese and obese normal responders.
Correlation of body mass index with outcome of in vitro fertilization in a developing country
Archives of Gynecology and Obstetrics, 2012
Aims and objective To correlate ovarian response to stimulation and IVF outcome according to the women's body mass index (BMI). Materials and methods Records of all patients who underwent IVF cycle in our institution from January 2008 to October 2010 were reviewed retrospectively. Three hundred and twenty-eight patients underwent 342 in vitro fertilization (IVF) cycles or intra-cytoplasmic sperm injection (ICSI) and were divided into four subgroups according to BMI; underweight, BMI \ 18.5; normal weight, 18.5-24.9; overweight, 25.0-29.9; and obese, [30.0. Results In our study, with increasing BMI negative co-relation was seen with clinical pregnancy rate (CPR) (P value = 0.040). Increased doses of gonadotropins were required with increase in patients BMI (P value = 0.045). In the present study, no difference was seen in the number of oocyte retrieved but a decreased fertilization and cleavage rate was seen with decreased number of cryopreserved embryos with increasing BMI. This study shows that poorer oocyte quality is seen with increasing BMI which results in reduced CPR. In our study no deleterious effect of low BMI was seen on IVF outcome and CPR. Conclusion Female obesity impairs IVF outcome potentially by impairing oocyte quality but does not affect ovarian response to stimulation.
Journal of assisted reproduction and genetics, 2008
Objective To determine if elevated body mass index in young women with normal ovarian reserve was associated with poorer ovarian response, difficulty at embryo transfer, and lower clinical pregnancy rates. Materials and methods Retrospective study of 417 first, fresh in vitro fertilization cycles performed between October 2004 and December 2006. All women were under the age of 35 and had normal cycle day 3 follicle stimulating hormone and estradiol levels. Subjects were divided into groups by BMI: <18.5, 18.5-24.9, 25-29.9, ≥30. Results Cancellation rates, peak estradiol levels, and mean number of oocytes retrieved were similar in all groups. There was a trend toward increasing difficulty in visualizing the air bubble at time of embryo transfer and lower implantation rates at higher body mass indices. Clinical and ongoing pregnancy rates were similar among groups. Conclusion Obesity in young women does not adversely affect clinical pregnancy rates in patients treated with in vitro fertilization.
Fertility and Sterility, 2015
Objective: To assess the effects of both male and female body mass index (BMI), individually and combined, on IVF outcomes. Design: Prospective cohort study. Setting: University fertility center. Patient(s): All couples undergoing first fresh IVF cycles, 2005-2010, for whom male and female weight and height information were available (n ¼ 721 couples). Intervention(s): None. Main Outcome Measure(s): Embryologic parameters, clinical pregnancy, and live birth incidence. Result(s): The average male BMI among the study population was 27.5 AE 4.8 kg/m 2 (range, 17.3-49.3 kg/m 2 ), while the average female BMI (n ¼ 721) was 25.2 AE 5.9 kg/m 2 (range, 16.2-50.7 kg/m 2 ). Neither male nor female overweight (25-29.9 kg/m 2 ), class I obese (30-34.9 kg/m 2 ), or class II/III obese (R35 kg/m 2 ) status was significantly associated with fertilization rate, embryo score, or incidence of pregnancy or live birth compared with normal weight (18.5-24.9 kg/m 2 ) status after adjusting for male and female age, partner BMI, and parity. Similar null findings were found between combined couple BMI categories and IVF success. Conclusion(s): Our findings support the notion that weight status does not influence fecundity among couples undergoing infertility treatment. Given the limited and conflicting research on BMI and pregnancy success among IVF couples, further research augmented to include other adiposity measures is needed. (Fertil Steril Ò 2014;-:---.
Body mass index and Ovarian response in an In-Vitro Fertilization Cycle
Rwanda Journal of Medicine and Health Sciences
Background: In-vitro fertilization (IVF) has established its place in the management of infertility cases that has defied conventional treatment. A successful In-vitro fertilization outcome is based on a good ovarian response to gonadotrophin stimulation. Body mass index has been identified as one factor that can affect ovarian response however; there is no consensus about its impact outcome. Objectives: To determine the effect of body mass index (BMI) on ovarian response in an Invitro fertilization cycle. Method: A Prospective cohort study to determine the response to Controlled Ovarian Hyperstimulation (COH) in women with normal and abnormal BMI in an IVF cycle. One hundred and four (104) consenting women undergoing non-donor IVF cycles in a university teaching hospital were recruited for the study. Selected participants had their body mass indices (BMI) assessed and classified into 3 groups: Normal weight (18.5-24.9kg/m 2), overweight (25-29.9kg/m 2) and obese (≥30kg/m 2). There were no underweight women-BMI <18.5kg/m 2. All the participants had Controlled Ovarian Hyperstimulation with the long agonist protocol. Selected participants had follicular count assessed using a transvaginal sonography on day 3, 5, 10 and at retrieval. The effect of ovarian response with the IVF treatment assessed based on total number of follicles and oocyte yield on the day of retrieval. Results: Female participants with normal weight women were thirty-six (34.6%), overweight were forty (38.5%) and obese, twenty-eight (26.9%). There was no statistical significant difference when the ages of women at presentation, total gonadotrophins requirements, duration of stimulation and number of oocytes retrieved were compared in the three groups. Conclusion: Increase in body mass index does not appear to have an adverse effect on ovarian response in an In-vitro fertilization cycle.
Reproductive BioMedicine Online, 2001
Decreased periovulatory human chorionic gonadotrophin (HCG) concentrations have been shown to be associated with diminished fertilization rates. This study evaluated if intra-follicular HCG concentration may be related to body mass in 247 IVF patients using their own oocytes and 58 patients receiving donor oocytes, and evaluated if such a relationship might affect IVF outcome. A significant inverse correlation (r =-0.353, P < 0.001) was observed between the body mass index (BMI) and intra-follicular HCG concentration. The mean HCG concentrations were significantly decreased (P < 0.001) in patients with a BMI >30 kg/m 2 compared with patients with a BMI of 20-30 kg/m 2 or BMI <20 kg/m 2 (17.6 versus 45.1 and 52.5%, respectively). The clinical pregnancy rates (P < 0.001) and embryo quality (P < 0.05) were significantly different for the three groups. In donor oocyte recipients, the pregnancy rate was significantly decreased (P < 0.0001) for recipients with a BMI >25 kg/m 2 compared with those with a BMI from 21-25 kg/m 2 and BMI <21 kg/m 2 (43.8 versus 72 and 76.5%, respectively). These data indicate that intra-follicular HCG concentration is inversely related to BMI, and may be related to a concurrent decrease in embryo quality and pregnancy rates.
Body Mass Index, Follicle-Stimulating Hormone and Their Predictive Value in In Vitro Fertilization
Journal of Assisted Reproduction and Genetics, 2004
The objective was to explore whether body mass and day 3 follicle-stimulating hormone have predictive value on odds of pregnancy after in vitro fertilisation. Few studies show that obesity produces a variety of alterations in the reproductive system, and that women with an elevation of day 3 FSH have declining ovarian function. Methods : The data of one-hundred-seventy-one women who underwent a standard regime of controlled ovarian hyperstimulation was analyzed with particular reference to variations in body mass and hormone levels. Results : By raising BMI and FSH (mIU/mL) by one unit, the odds for pregnancy were decreased by the respective factors 0.84 (95% confidence interval 0.73-0.97) and 0.77 (95% confidence interval 0.59-1.00). Conclusions : The results demonstrate that for the purpose of raising the odds of pregnancy BMI should be reduced. A low FSH value may cause the same effect. Nontheless, obesity and hormonal function may be independent risk factors for failure in assisted reproduction.
Clinical Obstetrics, Gynecology and Reproductive Medicine
Background: Many studies have suggested that female obesity has an impact on oocyte quality, embryo quality, and endometrial maturation in couples undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). In contrast, there are few data on the management of intrauterine insemination (IUI) in obese women. The objectives of the present study were to evaluate the clinical pregnancy and live birth rates in IVF/ICSI and IUI for overweight or obese women and to determine positive or negative predictive factors for pregnancy. Method: We analyzed long GnRH agonist or GnRH antagonist protocols with FSH/hMG for IVF/ICSI, and FSH/hMG alone for IUI. We classified the women into three groups: normal weight, overweight, and obesity. The latter group was divided into two obesity subgroups: class 1 and class 2/3. We recorded data on the patients' demographic, stimulation cycles, embryo cultures, and ongoing pregnancies obtained. For IVF/ICSI and IUI, we performed a univariate analysis of factors that were predictive of pregnancy and then selected a number for inclusion in a multivariate analysis. Results: The study included 1153 IVF/ICSI cycles and 541 IUI cycles. The clinical pregnancy and live birth rates in IVF/ICSI did not vary as a function of the female BMI. In IUI, the clinical pregnancy and live birth rates were significantly higher among obese women (21.6% and 17.7%, respectively) than among women of normal weight (12.2% and 9.3%, respectively; p<0.05). In IVF/ICSI and IUI, we did not observe an association between the spontaneous miscarriage rate and the BMI. In a univariate analysis, several predictive factors were found for IVF/ICSI and IUI. However, in a multivariate analysis, pregnancy in IVF/ICSI was notably predicted by the number of embryos obtained (≥5), whereas the absence of pregnancy in IUI was notably predicted by a monofollicular response to ovarian stimulation (p<0.001 for both). Conclusions: Our study did not find differences in clinical pregnancy and live birth rates as a function of female BMI in IVF/ICSI, and even evidenced higher rates among obese women in IUI. Nevertheless, women should be encouraged to lose weight if allowed by the setting and their age; this may decrease the incidence of obstetric complications during assisted reproductive technology programs.
Body mass index and fertility: is there a correlation with human reproduction outcomes
Gynecological Endocrinology, 2010
Please check these proofs carefully. It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.